Nanomedicinal products: a survey on specific toxicity and side effects.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Noorlander, Cornelle W
De Jong, Wim H
Kooi, Myrna W
Park, Margriet Vdz
Vandebriel, Rob J
Bosselaers, Irene Em
Scholl, Joep Hg
Geertsma, Robert E
MetadataShow full item record
TitleNanomedicinal products: a survey on specific toxicity and side effects.
Published inInt J Nanomedicine 2017, 12:6107-29
PubliekssamenvattingDue to their specific properties and pharmacokinetics, nanomedicinal products (NMPs) may present different toxicity and side effects compared to non-nanoformulated, conventional medicines. To facilitate the safety assessment of NMPs, we aimed to gain insight into toxic effects specific for NMPs by systematically analyzing the available toxicity data on approved NMPs in the European Union. In addition, by comparing five sets of products with the same active pharmaceutical ingredient (API) in a conventional formulation versus a nanoformulation, we aimed to identify any side effects specific for the nano aspect of NMPs. The objective was to investigate whether specific toxicity could be related to certain structural types of NMPs and whether a nanoformulation of an API altered the nature of side effects of the product in humans compared to a conventional formulation. The survey of toxicity data did not reveal nanospecific toxicity that could be related to certain types of structures of NMPs, other than those reported previously in relation to accumulation of iron nanoparticles (NPs). However, given the limited data for some of the product groups or toxicological end points in the analysis, conclusions with regard to (a lack of) potential nanomedicine-specific effects need to be considered carefully. Results from the comparison of side effects of five sets of drugs (mainly liposomes and/or cytostatics) confirmed the induction of pseudo-allergic responses associated with specific NMPs in the literature, in addition to the side effects common to both nanoformulations and regular formulations, eg, with liposomal doxorubicin, and possibly liposomal daunorubicin. Based on the available data, immunotoxicological effects of certain NMPs cannot be excluded, and we conclude that this end point requires further attention.
- A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements.
- Authors: Giannakou C, Park MV, de Jong WH, van Loveren H, Vandebriel RJ, Geertsma RE
- Issue date: 2016
- Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
- Authors: Mamidi RN, Weng S, Stellar S, Wang C, Yu N, Huang T, Tonelli AP, Kelley MF, Angiuoli A, Fung MC
- Issue date: 2010 Nov
- Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls.
- Authors: Giannakou C, Park MVDZ, Bosselaers IEM, de Jong WH, van der Laan JW, van Loveren H, Vandebriel RJ, Geertsma RE
- Issue date: 2020 Sep
- In vitro toxicity assessment of oral nanocarriers.
- Authors: Ciappellano SG, Tedesco E, Venturini M, Benetti F
- Issue date: 2016 Nov 15
- Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
- Authors: Khan MA, Owais M
- Issue date: 2006 Jul